Abstract
Despite convincing evidence from animal experiments, epidemiological studies linking the use of non-steroidal anti-inflammatory drugs (NSAIDs) with lower risk of breast and prostate cancer have been equivocal. One explanation for the inconsistencies among epidemiological studies may relate to individual differences in NSAID metabolism due to genetic polymorphisms in enzymes such as N -acetyltransferases and cytochrome P4502C9, which are known to be involved in the metabolic biotransformation of NSAIDs. The exclusion of these molecular biomarkers of individual susceptibility may have contributed to the inconsistent findings on the effects of NSAIDs in breast and prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
